- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Small cell lung cancer
- Meeting Date: July 2025
- Public Summary Document (PSD) July 2025 PBAC Meeting - (PDF)
- Public Summary Document (PSD) July 2025 PBAC Meeting - (Word)
Durvalumab – July 2025
Durvalumab; Solution concentrate for I.V. infusion, 120 mg in 2.4 mL, 500 mg in 10mL; Imfinzi®
Last updated
9 July 2025